Global Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market Size, Share, Growth Analysis, By Technology(Next-generation sequencing (NGS), polymerase chain reaction (PCR), and other techniques), By Biomarker(Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs)), By End user(Hospitals, diagnostic laboratories, and research centers), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35J2098 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 90 | Figures: 76

Breast Cancer Liquid Biopsy Market Competitive Landscape

The global breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth.

Breast Cancer Liquid Biopsy Market Top Player’s Company Profiles

  • Genomic Health (acquired by Exact Sciences) - United States
  • Illumina, Inc. - United States
  • Thermo Fisher Scientific - United States
  • QIAGEN - Germany
  • Myriad Genetics - United States
  • Personal Genome Diagnostics Inc. (PGDx) - United States
  • Bio-Rad Laboratories, Inc. - United States
  • Trovagene, Inc. (acquired by Admera Health) - United States
  • Exosome Diagnostics (acquired by Bio-Techne Corporation) - United States
  • Sysmex Corporation - Japan
  • Natera, Inc. - United States
  • Foundation Medicine (acquired by Roche) - United States
  • GRAIL, Inc. (acquired by Illumina) - United States
  • Menarini Silicon Biosystems - Italy
  • Angle plc - United Kingdom
  • Cynvenio Biosystems, Inc. - United States
  • DiaCarta, Inc. - United States

Breast Cancer Liquid Biopsy Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Breast Cancer Liquid Biopsy Market size was valued at USD 277 million in 2021 and is poised to grow from USD 417.03 million in 2023 to USD 1746.15 million by 2030, at a CAGR of 22.7% during the forecast period (2023-2030).

The breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth. 'Guardant Health - United States', 'Roche Diagnostics - Switzerland', 'Biocept, Inc. - United States', 'Genomic Health (acquired by Exact Sciences) - United States', 'Illumina, Inc. - United States', 'Thermo Fisher Scientific - United States', 'QIAGEN - Germany', 'Myriad Genetics - United States', 'Personal Genome Diagnostics Inc. (PGDx) - United States', 'Bio-Rad Laboratories, Inc. - United States', 'Trovagene, Inc. (acquired by Admera Health) - United States', 'Exosome Diagnostics (acquired by Bio-Techne Corporation) - United States', 'Sysmex Corporation - Japan', 'Natera, Inc. - United States', 'Foundation Medicine (acquired by Roche) - United States', 'GRAIL, Inc. (acquired by Illumina) - United States', 'Menarini Silicon Biosystems - Italy', 'Angle plc - United Kingdom', 'Cynvenio Biosystems, Inc. - United States', 'DiaCarta, Inc. - United States'

The increasing adoption of liquid biopsy techniques is a significant driver in the breast cancer liquid biopsy market. Compared to traditional tissue biopsies, liquid biopsies allow for the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers present in blood samples, enabling healthcare professionals to make more informed treatment decisions. Additionally, liquid biopsy has the potential to identify resistance mutations and minimal residual disease, which can aid in personalized treatment strategies, leading to improved patient outcomes and reduced healthcare costs.

There was a growing emphasis on non-invasive diagnostic methods, such as liquid biopsies, for early detection and monitoring of breast cancer.

North America led the way with a strong presence of key market players, advanced healthcare infrastructure, and growing adoption of liquid biopsy technologies. Europe demonstrated significant growth due to increased awareness, supportive government initiatives, and rising research and development activities. The Asia-Pacific region exhibited substantial potential, driven by a large patient pool, expanding healthcare expenditure, and increasing focus on personalized medicine. Latin America and the Middle East/Africa regions also experienced a gradual uptick in liquid biopsy adoption, with improving healthcare facilities and a greater emphasis on cancer diagnostics.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Liquid Biopsy Market
Buy Now GET FREE SAMPLE
Breast Biopsy Market
Buy Now GET FREE SAMPLE
Breast Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Breast Cancer Market
Buy Now GET FREE SAMPLE
Vacuum-Assisted Breast Biopsy Device Market
Buy Now GET FREE SAMPLE
Cancer Diagnostics Market
Buy Now GET FREE SAMPLE
Breast Imaging Technologies Market
Buy Now GET FREE SAMPLE
Next Generation Cancer Diagnostics Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Breast Cancer Liquid Biopsy Market

Report ID: SQMIG35J2098

$5,300
BUY NOW GET FREE SAMPLE